Press releases

Oncopeptides publishes Q2 report 2026

Invitation to presentation of the Q2 report 2026

Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe

Number of shares and votes in Oncopeptides

First patient enrolled in Oncopeptides’ glioblastoma study

Oncopeptides submits Type II variation application to EMA for Pepaxti label expansion into third line treatment

First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany

Oncopeptides to present clinical and translational data on Pepaxti at EHA 2026 in Stockholm

Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe

Bulletin from the Annual General Meeting in Oncopeptides

Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function

Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma